Literature DB >> 26585129

Chromatin Immunoprecipitation-Sequencing (ChIP-seq) for Mapping of Estrogen Receptor-Chromatin Interactions in Breast Cancer.

Kelly A Holmes1, Gordon D Brown1, Jason S Carroll2.   

Abstract

Chromatin immunoprecipitation-sequencing (ChIP-Seq) is a powerful tool which combines the established method of ChIP with next-generation sequencing (NGS) to determine DNA-binding sites of a protein of interest on a genome-wide level, importantly, allowing for de novo discovery of binding events. Here we describe ChIP-seq using the well-established example of estrogen receptor-α mapping in the MCF7 breast cancer cell line.

Entities:  

Keywords:  Chromatin; Chromatin immunoprecipitation; Enhancers; Estrogen receptor; Next-generation sequencing; Promoters

Mesh：

Substances：

Year:  2016        PMID： 26585129     DOI： 10.1007/978-1-4939-3127-9_8

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  5 in total

1.  TRIM33 drives prostate tumor growth by stabilizing androgen receptor from Skp2-mediated degradation.

Authors:  Mi Chen; Shreyas Lingadahalli; Nitin Narwade; Kate Man Kei Lei; Shanshan Liu; Zuxianglan Zhao; Yimin Zheng; Qian Lu; Alexander Hin Ning Tang; Terence Chuen Wai Poon; Edwin Cheung
Journal:  EMBO Rep       Date:  2022-07-04       Impact factor: 9.071

2.  TRIM37 Augments AP-2γ Transcriptional Activity and Cellular Localization via K63-linked Ubiquitination to Drive Breast Cancer Progression.

Authors:  Guimei Cui; Zhuoran Gao; Shiehong Chang; Nitin Narwade; Yitian Chen; Barun Poudel; Kate M K Lei; Weibo Zhang; Gang Li; Terence C W Poon; Edwin Cheung
Journal:  Int J Biol Sci       Date:  2022-07-04       Impact factor: 10.750

3.  Parallel factor ChIP provides essential internal control for quantitative differential ChIP-seq.

Authors:  Michael J Guertin; Amy E Cullen; Florian Markowetz; Andrew N Holding
Journal:  Nucleic Acids Res       Date:  2018-07-06       Impact factor: 16.971

4.  VULCAN integrates ChIP-seq with patient-derived co-expression networks to identify GRHL2 as a key co-regulator of ERa at enhancers in breast cancer.

Authors:  Andrew N Holding; Federico M Giorgi; Amanda Donnelly; Amy E Cullen; Sankari Nagarajan; Luke A Selth; Florian Markowetz
Journal:  Genome Biol       Date:  2019-05-13       Impact factor: 13.583

5.  ELF5 modulates the estrogen receptor cistrome in breast cancer.

Authors:  Catherine L Piggin; Daniel L Roden; Andrew M K Law; Mark P Molloy; Christoph Krisp; Alexander Swarbrick; Matthew J Naylor; Maria Kalyuga; Warren Kaplan; Samantha R Oakes; David Gallego-Ortega; Susan J Clark; Jason S Carroll; Nenad Bartonicek; Christopher J Ormandy
Journal:  PLoS Genet       Date:  2020-01-02       Impact factor: 5.917
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.